Study details
Enrolling now
PET/CT Characterization of Treatment Resistance
University of Wisconsin, Madison
NCT IDNCT05647564ClinicalTrials.gov data as of Apr 2026
Target enrollment
20
Study length
about 3 years
Ages
18+
Sex
Male only
Locations
1 site in WI
About this study
Researchers are testing different types of medical imaging to see how prostate cancer lesions become resistant to treatment. The trial is for men with advanced prostate cancer who are starting or already taking second-generation androgen receptor (AR) targeted therapy. Participants will be in it for at least 9 months, and up to 2 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.F-fluorodeoxyglucose positron emission tomography (FDG PET)
- 2.Prostate-specific membrane antigen positron emission tomography (PSMA PET)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
Procedures
imaging
Body systems
Oncology